ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,361Medicare Part D Prescriptions Filled, Including Refills

Rank: 81 out of 1269

$446K Total Retail Price of All Prescriptions

Rank: 191 out of 1269

278 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
80% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 278 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 8,188 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
AMLODIPINE BESYLATE 351 327 1 2
FUROSEMIDE 342 312 2 5
METOPROLOL TARTRATE 310 273 3 6
LISINOPRIL 301 234 4 1
LEVOTHYROXINE SODIUM 245 222 5 4
TRAMADOL HCL 206 186 6 16
OMEPRAZOLE 168 148 7 8
MIRTAZAPINE 166 160 8 24
CITALOPRAM HBR 161 152 9 21
LIDODERM 149 147 10 56
SIMVASTATIN 148 129 11 3
DONEPEZIL HCL 148 146 11 22
LANTUS 135 121 13 39
TRAZODONE HCL 134 116 14 36
HYDROCHLOROTHIAZIDE 133 105 15 10
CLOPIDOGREL 124 113 16 32
TAMSULOSIN HCL 121 112 17 31
LACTULOSE 121 112 17 67
METFORMIN HCL 114 99 19 9
RISPERIDONE 113 94 20 43
LOVASTATIN 112 105 21 30
GABAPENTIN 110 92 22 17
TRIAMCINOLONE ACETONIDE 104 91 23 131
METOPROLOL SUCCINATE 101 90 24 13
RANITIDINE HCL 99 76 25 27
PRAVASTATIN SODIUM 93 71 26 11
NAMENDA 90 90 27 38
PLAVIX 87 82 28 47
LEVETIRACETAM 86 68 29 55
SULFAMETHOXAZOLE-TRIMETHOPRIM 85 79 30 84
ZOLPIDEM TARTRATE 83 47 31 19
OXYCODONE HCL 82 51 S2 32 34
ATENOLOL 77 77 33 14
NYSTATIN 75 61 34 119
IBUPROFEN 75 73 34 73
SERTRALINE HCL 75 74 34 23
OLANZAPINE 73 61 37 89
ATORVASTATIN CALCIUM 70 54 38 7
JANTOVEN 70 70 38 52
HYDRALAZINE HCL 69 66 40 48
POTASSIUM CHLORIDE 68 59 41 26
PANTOPRAZOLE SODIUM 68 57 41 18
DIVALPROEX SODIUM 68 17 41 54
POLYETHYLENE GLYCOL 3350 67 54 44 50
SANTYL 66 66 45 101
QUETIAPINE FUMARATE 66 48 45 53
CARVEDILOL 59 58 47 29
KLOR-CON M20 59 53 47 60
OXYCODONE-ACETAMINOPHEN 53 32 S2 49 44
BACLOFEN 52 38 50 103
ESCITALOPRAM OXALATE 51 41 51 58
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 9, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.